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ABSTRACT
Introduction: Several studies have shown that statins suppress the progression of dia-
betic nephropathy. However, few reports have directly compared the renoprotective
effects between potent and conventional statins.
Materials and Methods: Patients with diabetic nephropathy, selected as those with a
serum creatinine level of 0.9–1.5 mg/dL and simultaneously having either microalbuminu-
ria or positive proteinuria, were randomly assigned to one of three groups: a conventional
diet therapy group, a group given 10 mg of pravastatin and a group given 10 mg of
atorvastatin. Renal function was evaluated before and after a 12-month period of therapy.
Results: The atorvastatin group had a significant decrease in low-density lipoprotein
cholesterol at 3 months and thereafter compared with the other groups. The urinary albu-
min-to-creatinine ratio significantly decreased in the atorvastatin group; the degree of this
decrease was significantly greater than that in the diet therapy group. The kidney function
estimated with cystatin C (CysC) and the estimated glomerular filtration rate calculated
from CysC were significantly preserved in the atorvastatin group compared with the pra-
vastatin group. In a multivariate regression analysis, the use of atorvastatin was the only
explanatory variable for the changes in CysC; this was independent of changes in low-
density lipoprotein cholesterol.
Conclusions: Atorvastatin is more effective than pravastatin for the prevention of
increase in CysC, and this renoprotective effect was considered to a result of the pleiotro-
pic effect of atorvastatin independent of its lipid-lowering effect. This study was registered
with UMIN (no. UMIN 000001774).
INTRODUCTION
Diabetes mellitus is a major cause of chronic kidney disease
(CKD). Evidence has been growing that intensive glycemic con-
trol or antihypertensive therapy with antagonists of the renin–
angiotensin system suppresses the progression of CKD in
patients with diabetes1,2. However, optimal management strate-
gies for diabetic nephropathy have not been established3.
We previously reported that administration of a statin
decreases albuminuria in a rat model of experimental diabetic
nephropathy through pleiotropic effects4. To date, many lines
of clinical evidence have reported that dyslipidemia is con-
nected with the progression of kidney diseases5–7, probably as a
result of lipotoxicity8. Large-scale meta-analyses have shown
that statin therapy has a protective effect against deterioration
of renal function in CKD patients with baseline albuminuria
above 30 mg/day9,10.
Lipid-lowering therapy by statins might also be useful in
reducing albuminuria in type 2 diabetic patients with an early
stage of diabetic nephropathy11. Furthermore, several lines of
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CLINICAL TRIAL
evidence show that potent statins, such as atorvastatin and
rosuvastatin, prevent deterioration of kidney function in dia-
betic patients with CKD12,13. However, it has not been fully
determined whether the renoprotective effect of statins is inde-
pendent of their lipid-lowering action. In addition, no reports
are available that directly compare conventional statins and
potent statins in terms of their renoprotective effects against
CKD in patients with diabetes. In the current study, we evalu-
ated the effects of pravastatin and atorvastatin on renal
outcomes in diabetic patients with early diabetic nephropathy.
MATERIALS AND METHODS
The present research project was a prospective study spanning
12 months, and was a randomized, open-label, clinical study.
Patients were recruited from 2008 through 2010 from Kanaza-
wa University Hospital, Toyama City Hospital and Fukui-ken
Saiseikai Hospital. The enrolment criteria were as follows: the
participants had to (i) be diabetic patients currently being seen
on an outpatient basis, who had not been treated with statin
therapy within 3 months of the start of the study; (ii) had a
low-density lipoprotein cholesterol (LDL-C) of 120–150 mg/dL
two consecutive times; and (iii) had a blood serum creatinine
(Cr) level of 0.9–1.5 mg/dL simultaneously with a test result of
either microalbuminuria (≥30 mg/gCr) or positive proteinuria
(qualitative) more than twice. Microalbuminuria and protein-
uria were derived from proper laboratory tests. Participants
could have either type 1 or type 2 diabetes, could be any age
between 18 and 80 years, and could be either sex. Exclusion
criteria were as follows: (i) poor blood pressure (BP) control
(160/100 mmHg or higher); (ii) glycemic control that was
either poor or unstable (the most recent glycated hemoglobin
[HbA1c; National Glycohemoglobin Standardization Program
(NGSP) value] was 10% or higher, or change in HbA1c over
the most recent 3 months was 2% or higher); (iii) patients with
hematuria; (iv) patients with a urinary tract infection; and (v)
patients with a past history of atherosclerosis, such as coronary
heart disease, stroke and peripheral artery disease. Informed
consent to the study was obtained in writing from all study
participants. The research protocol was approved by the ethics
committee of each facility involved, and the study was carried
out in compliance with the Declaration of Helsinki.
Figure S1 summarizes the participants’ progress through the
trial from the perspective of the Consolidated Standards of
Reporting Trials criteria for randomized trials. After a prior
assessment, 120 patients were randomly assigned to one of
three groups: a group that would be treated with diet therapy,
a group that would be given a statin (pravastatin) and a group
that would be treated with a potent statin (atorvastatin). The
subjects’ identiﬁcation number on their medical chart deter-
mined their group. Over the 12 months of the study, 43 of the
patients would be provided with dietary guidance (the diet ther-
apy group). The dietary guidance was provided by a national
registered dietitian at the hospitals at least once every
3 months. The dietitian checked the meals and gave the
participants some advice about the diet for diabetic nephropa-
thy, such as restriction of protein (~0.8 g/kg) and salt intake
(<6 g/day). The other 28 patients would be given 10 mg/day of
pravastatin in addition to being provided with dietary guidance
(the pravastatin group), and 35 patients would be given 10 mg/
day of atorvastatin in addition to dietary guidance (the ator-
vastatin group).
Blood and urine samples were collected at minimum inter-
vals of 3 months. If a patient began dialysis during the
12 months of the monitoring period, a ﬁnal evaluation of that
patient was carried out at that point. It was decided that, as a
rule, the medications listed here would not be added to a
patient’s regimen during the monitoring period: therapeutic
agents for the treatment of hyperlipidemia other than statins
(ﬁbrates, ezetimibe, nicotinic acid, probucol, resins, ethyl icosap-
entate formulations and others) and medications having an
effect of reducing proteinuria, such as dipyridamole. Adminis-
tration of the following would be carried out only at the mini-
mum necessary level during the monitoring period: non-
steroidal anti-inﬂammatory drugs and antibiotics that affect
renal function. It was decided that standard therapies consisting
primarily of angiotensin-converting enzyme (ACE) inhibitors or
angiotensin II receptor blockers (ARBs) would be given with
the aim of keeping BP under 130/80 mmHg (or under 125/
75 mmHg if proteinuria 1 g/day or higher was observed).
Adjustments for glycemic control would be made as necessary
with oral medications or insulin dosages, in addition to diet
and exercise programs, to keep HbA1c under 6.9% (NGSP)
according to the guidelines of the Japan Diabetes Society14.
Measurements
Height, bodyweight, BP, fasting blood values, and urine values
were measured at baseline and at every consultation for
3 months. Body mass index (BMI) was calculated as weight/
height2 (kg/m2). Total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C) and triglycerides (TGs) were measured
using commercially available kits. LDL-C was calculated by the
Friedewald method. HbA1c was measured using the Tosoh G8
analyzer (Tosoh, Tokyo, Japan) at Kanazawa University Hospi-
tal, the Tosoh G7 analyzer (Tosoh, Tokyo, Japan) at Toyama
City Hospital and the ADAMS A1c HA-8180 analyzer (ARK-
RAY, Kyoto, Japan) at Fukui-ken Saiseikai Hospital. Quality
control of HbA1c measurements was carried out using the
standard certiﬁed by the Japanese Diabetes Society (JDS).
HbA1c values were converted to NGSP values using the for-
mula provided by the JDS: HbA1c (NGSP) = 1.02 9 HbA1c
(JDS) + 0.2515.
Serum cystatin C (CysC) was measured using nephelometry
at Kanazawa University Hospital, the gold colloid aggregation
method at Toyama City Hospital and the latex agglutination
turbidimetric immunoassay at Fukui-ken Saiseikai Hospital; that
is, in different ways at the different facilities. However, accord-
ing to in-house test reports, there is an extremely strong corre-
lation between nephelometry and the gold colloid aggregation
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method (r = 0.996), and between the gold colloid aggregation
method and the latex agglutination turbidimetric immunoassay
(r = 0.999). The urinary albumin-to-Cr ratio (U-Alb/Cr) was
measured using the ﬁrst morning urine. Albumin was mea-
sured using immunonephelometry. The estimated glomerular
ﬁltration rate (eGFR) was calculated using the following for-
mula recommended for Japanese patients16: eGFR (mL/min/
1.73 m2) = 194 9 Cr-1.094 9 age-0.287 9 0.739 (if female). The
eGFR using serum CysC (eGFRcys) was calculated using the
following formula recommended for Japanese patients17: eGFR-
cys (mL/min/1.73 m2) = (104 9 Scys-1.019 9 0.996Age 9 0929
[if female]) – 8.
Statistical Analyses
Characteristics of the baseline proﬁles were compared among
the three groups using the v2-test for categorical variables, and
one-way analysis of variance (ANOVA) and the post-hoc test
(Bonferroni method) for continuous variables. In this interven-
tion study, we used the changes in renal function (eGFR,
U-Alb/Cr, CysC) over the 12-month period for primary out-
come. Analysis of covariance (ANCOVA) with repeated measure-
ments and the post-hoc test (Bonferroni method) were used to
evaluate the differences in changes of LDL-C and renal func-
tion among the three groups. Multiple linear regression analyses
were used to evaluate the factors that affected the 12-month
changes in CysC. Age, sex, baseline bodyweight, baseline sys-
tolic BP, use of ACE inhibitors or ARBs during follow up, use
of pravastatin and use of atorvastatin, and 12-months’ changes
in LDL-C, HbA1c, systolic BP and bodyweight were used as
explanatory variables. Statistical analyses were carried out using
the Japanese version of the Statistical Package for the Social
Sciences (SPSS version 11.0; SPSS Japan Inc., Tokyo, Japan). A
P-value of <0.05 was taken as statistically signiﬁcant.
RESULTS
Baseline Clinical Characteristics
Table 1 shows the baseline clinical characteristics according to
the different lipid-lowering therapies. There were no statistical
differences in sex, diabetes type, age, BMI, duration of diabetes,
systolic BP, use of ACE inhibitors or ARBs, HbA1c, TGs,
HDL-C, or diabetes treatment method among the three groups.
However, TC and LDL-C were higher in the atorvastatin group
than in the diet therapy group.
Changes in Lipids and Other Metabolic Variables
Table 1 shows the differences in the clinical characteristics
between the measurements at baseline and at 12 months. In
the diet therapy group, no signiﬁcant differences were observed
in lipids, systolic BP and HbA1c at 12 months. In the pravasta-
tin group and the atorvastatin group, signiﬁcant decreases were
observed in TC (P = 0.024 for the pravastatin group and
P < 0.001 for the atorvastatin group) and in LDL-C (P = 0.002
for the pravastatin group and P < 0.001 for the atorvastatin
group). In contrast, no signiﬁcant differences were observed in
HDL-C, TGs, systolic BP and HbA1c during the follow-up per-
iod.
The pravastatin and atorvastatin groups showed signiﬁcant
reductions in LDL-C at 12 months compared with the baseline.
In the atorvastatin group, LDL-C was signiﬁcantly lower at
3 months and thereafter compared with the other two groups.
Renal Outcomes
The means of eGFR (mL/min/1.73 m2) were 63.6 – 16.8 at
baseline and 61.3 – 16.3 at 12 months. There was no patient
who required dialysis treatment during the follow-up period.
Figure 1a shows the percent changes in log(U-Alb/Cr)
among the three groups. A signiﬁcant decrease in log (U-Alb/
Cr) was seen at 12 months in the atorvastatin group, and the
values were signiﬁcantly lower compared with the diet therapy
group.
Figure 1b shows the changes in eGFR according to the three
categories of lipid-lowering therapy. Compared with the diet
and pravastatin groups, the atorvastatin group showed signiﬁ-
cant improvement in eGFR at 3 months; however, no differ-
ences were observed at 6 months and after among the three
groups. As shown in Figure 1 c, CysC was signiﬁcantly lower
in the atorvastatin group at 6 months and at 12 months com-
pared with the pravastatin group. As shown in Figure 1d, eG-
FRcys (eGFR calculated from CysC) was signiﬁcantly improved
in the atorvastatin group at 12 months compared with the pra-
vastatin group.
Cystatin C was signiﬁcantly lower in the atorvastatin group
at 6 months and at 12 months compared with the pravastatin
group. These results suggest that atorvastatin had a beneﬁcial
effect on the change in CysC.
We used multivariate regression analysis to review possible
connections with other factors that might affect the change in
CysC. In multivariate regression analysis, the use of atorvasta-
tin was the only explanatory variable for the changes in
CysC; this was independent of changes in LDL-C, as well as
of sex, age, bodyweight, systolic BP, use of ACE inhibitors or
ARBs and changes in HbA1c (Table S1). The results were
similar when we evaluated the associations in the 102 patients
after excluding four patients (one in the diet therapy group,
one in the pravastatin group and two in the atorvastatin
group). We also used multivariate regression analysis to
review possible connections with other factors that might
affect the change in eGFRcys among the three groups (Table
S1). ‘The use of atorvastatin’ and ‘percent change in LDL-C
at 12 months’ were the explanatory variable for the changes
in eGFRcys.
DISCUSSION
The present study compared the renoprotective effects in dia-
betic patients with mild CKD during 1 year between three
lipid-lowering therapies: diet therapy, pravastatin and atorvasta-
tin. Atorvastatin, but not pravastatin, signiﬁcantly decreased the
U-Alb/Cr from the baseline, and the degree of this decrease
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was signiﬁcantly greater compared with the diet therapy.
Although there were no signiﬁcant differences in the changes
of eGFR among the three groups, atorvastatin signiﬁcantly pre-
served CysC levels and eGFRcys compared with paravastatin.
These ﬁndings showed that the renoprotective effects are differ-
ent between atorvastatin and pravastatin, and that atorvastatin
is more useful than pravastatin for its renoprotective effect in
diabetic patients with early diabetic nephropathy.
Some studies have reported that atorvastatin has a protective
effect on renal function9,10,12,18–21. In the Greek Atorvastatin
and Coronary-heart-disease Evaluation (GREACE) study,
aggressive administration of atorvastatin induced an increase in
Cr clearance (CrCl) after 6 weeks, and the effect was continued
for up to 48 months18. However, in the present study, eGFR
did not change during the 12 months in the atorvastatin group,
as well as in the diet group and pravastatin group. Our study
ﬁndings are in concert with a previous single arm study22, that
in patients with CKD, administration of rosuvastatin, one of
the other strong statins, at a dose of 2.5 mg for 24 weeks, sig-
niﬁcantly decreased U-Alb/Cr and CysC, but did not change
eGFR.
These differences in the results might due to the low dose of
statins used in the present study. In our study, we used 10 mg/
day of atorvastatin, whereas, in the GREACE study, atorvastatin
was started at 10 mg/day, and the dose was titrated up to a
maximum of 80 mg/day (mean dose 24 mg/day)18. The Treat-
ing to New Targets study showed that atorvastatin administra-
tion increased eGFR in a dose-dependent manner, and the
increase was signiﬁcantly greater in patients who received a
high dose (80 mg/day) compared with those who received a
low dose (10 mg/day)19.
Differences in the renal function of the study participants
might also affect the results. In the GREACE study, renoprotec-
tive effects have been particularly prominent with respect to
early-stage renal disease. The Collaborative Atorvastatin Diabe-
tes Study also showed that atorvastatin improves eGFR in
patients with type 2 diabetes with albuminuria, but not in those
with normo-albuminuria12. Similar to the atorvastatin, pravasta-
tin also prevented the decrease in eGFR in patients with mod-
erate CKD (eGFR <40 mL/min/1.73 m2), but not in those with
mild CKD (eGFR >60 mL/min/1.73 m2)23, 24. In our study
patients, mean eGFR (61.4–66.3 mL/min/1.73 m2) was rela-
tively preserved even though they had albuminuria/proteinuria.
This might relate to the result that eGFR did not change in
our study participants.
Furthermore, the short follow-up period may also affect the
results. The Protection Against Nephropathy in Diabetes with
Atorvastatin trial reported that in patients with type 2 diabetes
Table 1 | Baseline and follow-up clinical features of laboratory markers by treatment for hyperlipidemia
Diet therapy group Pravastatin group Atorvastatin group
0 M 12 M P 0 M 12 M P 0 M 12 M P
No. patients 43 28 35
Men: Women 38:5 25:3 29:6
Type 1: type 2 diabetes 1:42 1:27 2:33
Age (years) 63 – 11 63 – 11 60 – 11
Diabetes duration (years) 8.0 – 8.4 8.4 – 6.1 6.4 – 3.5
ACEI or ARBS (+: -) 20:23 20:23 1.000 14:14 14:14 1.000 17:18 18:17 0.085
Diabetes treatment 5:30:8 5:30:8 1.000 3:14:11 3:14:11 1.000 7:21:7 7:21:7 1.000
(Diet: OHA: insulin)
BMI (kg/m2) 24.3 – 3.2 24.7 – 3.3 0.200 23.4 – 3.0 23.9 – 3.2 0.154 23.8 – 3.3 23.7 – 2.9 1.000
Systolic blood pressure (mmHg) 128 – 12 129 – 12 1.000 129 – 13 125 – 16 0.385 129 – 14 126 – 13 0.557
HbA1c (NGSP) (%) 7.3 – 0.8 7.4 – 1.0 1.000 7.4 – 1.1 7.4 – 1.1 1.000 7.7 – 1.5 7.7 – 1.5 1.000
TC (mg/dL) 186 – 27 193 – 34 0.508 193 – 32 175 – 27 0.024 205 – 35† 153 – 24 <0.001
LDL-C (mg/dL) 109 – 25 109 – 25 1.000 118 – 28 98 – 21 0.002 127 – 25† 74 – 16 <0.001
HDL-C (mg/dL) 50 – 14 52 – 19 0.127 49 – 10 48 – 11 1.000 49 – 13 51 – 15 0.333
TG (mg/dL) 134 – 62 154 – 136 0.404 146 – 87 154 – 87 1.000 153 – 79 137 – 92 0.812
eGFR (mL/min/1.73 m2) 61.4 – 16.0 58.3 – 13.0 0.077 66.3 – 17.0 63.5 – 17.0 0.313 64.0 – 18.0 63.2 – 18.0 1.000
eGFRcys (mL/min/1.73 m2) 90.1 – 26.9 88.3 – 27.0 0.706 83.1 – 20.1 79.1 – 21.9 0.091 92.5 – 27.9 94.9 – 29.5 0.471
Cystatin C (mg/L) 0.89 – 0.30 0.90 – 0.28 1.000 0.92 – 0.19 0.99 – 0.28 0.053 0.87 – 0.23 0.85 – 0.21 1.000
Log(U-Alb/Cr) 1.4 – 0.8 1.5 – 0.8 0.625 1.6 – 1.1 1.5 – 1.2 1.000 1.3 – 0.6 1.1 – 0.7 0.041
Data values are mean – standard deviation. The v2-test for categorical variables and one-way analysis of variance for continuous variables were
used for the analyses. Repeated measures analysis of covariance was used to compare the details between 0 month and 12 months. ACEI, angio-
tensin-converting enzyme inhibitors; ARBS, angiotensin II receptor blockers; BMI, body mass index; Diet, diet therapy; eGFR, estimated glomerular
filtration rate; eGFRcys, estimated glomerular filtration rate using serum cystatin C; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein
cholesterol; insulin, insulin therapy; LDL-C, low-density lipoprotein cholesterol; Log(U-Alb/Cr), log-transformed urinary albumin/creatinine; M, months;
OHA, oral hypoglycemic agent; TC, total cholesterol; TG, triglyceride. †P < 0.05 vs diet therapy group by post-hoc test (Bonferroni).
ª 2014 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd J Diabetes Invest Vol. 6 No. 3 May 2015 349
C L I N I C A L T R I A L
http://onlinelibrary.wiley.com/journal/jdi Effect of statin on diabetic nephropathy
with early renal disease, no statistical difference was observed in
renal function between those taking high- (80 mg/day) or
low-dose (10 mg/day) atorvastatin over 2.1 years25. However,
the study periods of this trial and our present study are shorter
than those of the GREACE study and the Treating to New
Targets study. Therefore, it is difﬁcult to compare these results
directly.
In the present study, U-Alb/Cr was signiﬁcantly improved in
the atorvastatin group, but not in the pravastatin group, at
12 months compared with the baseline. More strikingly, the
change in CysC was signiﬁcantly smaller, and eGFRcys was sig-
niﬁcantly higher in the atorvastatin group compared with the
pravastatin group. To date, there are no reports that have com-
pared the preventive effect on renal dysfunction progression
between atrovastatin and other statins using CysC and eGFRcys
as indices.
To date, eGFR and U-Alb/Cr calculated from serum creati-
nine (sCr) is commonly used for the diagnosis of CKD. How-
ever, because sCr does not change in a mild to moderate
decrease in creatinine clearance (CrCl), eGFR and U-Alb/Cr cal-
culated by sCr might not be effective to evaluate the renal func-
tion in a relatively early stage of CKD. In recent years, CysC has
been tested as a better marker that detects an early decrease of
CrCl in mild CKD. CysC is a low molecular mass serum protein
that is freely ﬁltered by the glomerulus and reabsorbed by the
proximal kidney tubule. Serum Cr increases when CrCl
decreases to 31–50 mL/min, whereas CysC starts to increase
from a milder CrCl decrease of 51–70 mL/min26. Because eGFR
is calculated based on the serum Cr, it does not reﬂect a mild
decrease in CrCl in patients with relatively high CrCl. Thus,
using the CysC and eGFRcys as indices for renal function could
detect slight changes in CrCl, especially in patients with an early
stage of CKD. Therefore, in the present study, we compared the
differences of these makers for renal function. Together with the
discussion here, longer study is required to conclude the effect
of atorvastatin on eGFR calculated from sCr.
We postulate the reasons for the discrepancy between a sig-
niﬁcant, but subtle, effect on U-Alb/Cr and the obvious effect
throughout the study period on CysC of atorvastatin beyond
pravastatin. First, the Cr serum level is affected by diet, inﬂam-
mation, age, sex, muscle mass, exercise and other parameters,
whereas the CysC serum level is not affected by these factors27.
Indeed, the standard deviation was much larger in U-Alb/Cr
than CysC in the present study. Second, the discrepancy might
suggest the speciﬁc mechanism underlying the protective effect
of atorvastatin on renal function; statin might more preferen-
tially improve GFR rather than hyperﬁltration or size/charge









































































Figure 1 | Time-course of changes in urinary albumin excretion (U-Alb/
Cr), estimated glomerular filtration rate (eGFR), serum cystatin C (CysC)
and estimated glomerular filtration rate using serum cystatin C
(eGFRcys) from baseline across the three groups of cholesterol
treatment. Data values are mean – standard error. Black circles, diet
therapy group; black squares, pravastatin group; black triangles,
atorvastatin group. Repeated measures analysis of covariance and the
post-hoc test (Bonferroni) was used for the analysis. *P < 0.05 vs
baseline values. †P < 0.05 vs the diet therapy group. ‡P < 0.05 vs the
pravastatin group. Log(U-Alb/Cr), log-transformed urinary albumin/
creatinine.
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that statins gradually increase GFR as a result of their pleio-
trophic actions, such as endothelial vasodilation (and the
increase in circulating plasma volume accompanying it), regres-
sion of atheromatous renovascular stenosis, regression of inti-
mal hyperplasia in arcuate arteries or arteriosclerosis
progression delay in afferent arterioles18. Future study evaluat-
ing the effect of atorvastatin stratiﬁed by impaired GFR-domi-
nant and albuminuria/proteinuria-dominant types of diabetic
nephropathy might test this hypothesis. Interestingly, a similar
result was reported as a protective effect of an Nrf2 activator
bardoxolone methyl on kidney function in CKD with type 2
diabetes28. Patients receiving bardoxolone methyl had a signiﬁ-
cant increase in eGFR and had a slight, but signiﬁcant, increase
in the U-Alb/Cr as compared with placebo at 24 and 52 weeks.
Therefore, the effect of statins on the Keap1/Nrf2 system in the
kidney might be a novel issue worth investigating. Indeed, sev-
eral statins were reported to activate Nrf2 signaling in the
liver29, embryonic ﬁbroblasts30, vascular smooth muscle cells31
and brain32.
The present results from multiple regression analyses showed
that the use of atorvastatin affected CysC independently of its
cholesterol-lowering effect. The previous prospective studies in
diabetic patients with progressive renal disease compared the
renoprotective effect of atorvastatin and rosuvastatin for CKD
patients20, and showed that the renoprotective effect was stron-
ger in atorvastatin (80 mg/day) than high-dose rosuvastatin
(40 mg/day), whereas rosuvastatin had stronger cholesterol-low-
ering effects. These results suggest that the renoprotective effect
of atorvastatin would be due to pleiotropic effects beyond its
lipid-lowering effect.
The strength of the present study is that it is a direct com-
parison between atorvastatin and pravastatin with respect to
their effect on renal function. There has been no previous
report that directly compared the effect of potent statins and
conventional statins on the progression of CKD in patients
with diabetes. Furthermore, there have been no reports that
compared the preventive effect on renal dysfunction progres-
sion between atorvastatin and other statins using CysC as an
index. Previous studies23,24 suggest that the renoprotective effect
of pravastatin is limited to moderate to severe kidney disease,
and that atorvastatin has a superior effect on early diabetic
nephropathy through its pleiotropic effect. Such properties of
the different classes of statins might underlie the advantage of
atorvastatin over pravastatin in the renoprotective effect,
because the subjects enrolled in the present study had relatively
mild CKD.
There were several limiting factors in the present study. First,
CysC was measured in different ways at the different facilities.
However, according to in-house test reports, there is an extre-
mely strong correlation between nephelometry and the gold
colloid aggregation method, and between the gold colloid aggre-
gation method and the latex agglutination turbidimetric immu-
noassay. As a result, we postulate that as long as CysC is
measured using the same method, there is a strong possibility
that similar results can be obtained. Second, the number of
patients happened to be different in the three groups because
we used the participants’ identiﬁcation number on their medi-
cal chart to determine their group. However, baseline character-
istics, such as sex, age and blood pressure, were not different
among the three groups, and the results observed in the present
study are independent of these confounding factors, which
affect the changes in renal function. Finally, kidney biopsy was
not carried out in all cases. In particular, three patients out of
14 patients with macroalbuminuria were not complicated with
diabetic retinopathy. We ruled out malignancy-associated mem-
branous nephropathy and other nephritis syndrome clinically
in these patients.
In conclusion, the present study showed that atorvastatin
inhibits the elevation of CysC in diabetic patients to a greater
extent than pravastatin. In addition, this renoprotective effect
was considered to be the result of the pleiotropic effect of ator-
vastatin independent of its lipid-lowering effect. For lipid man-
agement in diabetic patients, atorvastatin is more effective than
pravastatin in terms of preventing increase in CysC.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Table S1 | The variables associated with 12-month change in cystatin C and estimated glomerular ﬁltration rate using serum cysta-
tin C.
Figure S1 | Consolidated Standards of Reporting Trials ﬂow diagram. Summary of recruitment, randomization and participants’
progress through the trial. After a prior assessment, 120 patients were randomly assigned to one of three groups: a group that
would be treated with diet therapy, a group that would be given a statin (pravastatin) and a group that would be treated with a
potent statin (atorvastatin). The patients’ identiﬁcation number on their medical chart determined their group. Over the 12 months
of the study, 43 of the patients would be provided with dietary guidance (the diet therapy group). The other 28 patients would be
given 10 mg/day of pravastatin in addition to being provided with dietary guidance (the pravastatin group), and 35 patients would
be given 10 mg/day of atorvastatin in addition to dietary guidance (the atorvastatin group).
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